Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIR® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19

NCT05185284 is registered in ClinicalTrials.gov with Promomed, LLC as lead sponsor.

NCT NCT05185284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05185284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Randomized Multicenter Comparative Study on the Efficacy and Safety of AREPLIVIR® (Favipiravir) for Parenteral Administration (PROMOMED RUS LLC, Russia) in Hospitalized Patients With COVID-19
Lead sponsor
Promomed, LLC
Phase
Phase 3
Overall status
Completed
Start date
August 11, 2021
Completion date
December 30, 2021
Enrollment
217 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19